Xcelience Reduces Time to Phase I Studies by 17 Weeks Using API into Capsule Services; Celebrates 100th Xcelodose® GMP Batch

Tampa, FL (June 10, 2009) – Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA). API into Capsule projects are on average completed 45 percent faster than traditional formulation efforts, and in some specific cases we have saved our clients as much as 17 weeks.

“Today’s molecule is under pressure” says Derek Hennecke, CEO and President. “We need to work smarter with clients to make the best choices, often with limited material. One of the best decisions we made was to put our money on Xcelodose®. We were the first CRO in North America to do so, we’ve built up industry leading expertise, and this month we are proud to announce our 100th GMP batch.

"Our defined API into Capsule program is a true differentiator, but not the only one” adds V.P. Randall H. Guthrie, “Xcelience combines decades of drug development experience, state-of-the-art equipment, a strong audit history, and sound financial management to deliver solutions that enable our clients to rely on us to accelerate drug development programs and meet critical milestones.”

Xcelience is also announcing a strategic expansion focused on areas of proven strength: low weight fills and potent compounds for API into capsule, continued expansion and growth of its formulation development team, implementation of UPLC analytical capability, investment in x-ray diffraction for preformulation activities, and blister packaging in support of client’s clinical supply needs. Development of the purpose-built Grace Street expansion continues as planned.

Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab.

About Xcelience: Keep on top of new developments in Xcelience and throughout the drug development industry by following us on Twitter www.twitter.com/Xcelience. For more detailed information about Xcelience, visit www.xcelience.com.